Top

Published in:

01-07-2021 | Heart Failure

The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review

Authors: Simon W. Rabkin, Jacky K. K. Tang

Published in: Heart Failure Reviews | Issue 4/2021

Abstract

The objective was to evaluate the diagnosis of heart failure with preserved ejection fraction (HFpEF) using the biomarkers, growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3), and soluble ST2 (sST2), and to determine whether they can differentiate HFpEF from heart failure with reduced ejection fraction (HFrEF). Medline and Embase databases were searched with the terms diastolic heart failure or HFpEF, biomarkers, and diagnosis, limited to years 2000 to 2019. There were significantly and consistently higher levels of GDF-15, Gal-3, and sST2 in HFpEF compared to no heart failure. Importantly, the magnitude of the increase in GDF-15 or Gal-3 and possibly sST2,correlated with a greater degree of diastolic dysfunction. There were no significant differences between GDF-15, Gal-3, and sST2 in patients with HFpEF vs HFrEF. In the studies assessing these three biomarkers, BNP was significantly greater in heart failure than controls. Furthermore, BNP was significantly higher in HFrEF compared to HFpEF. The diagnostic utility of GDF-15, Gal-3, and sST2 compared to BNP was evaluated by comparing ROC curves. The data supports the contention that to distinguish HFpEF from HFrEF, an index is needed that incorporates GDF-15, Gal-3, or sST2 as well as BNP. The three biomarkers GDF-15, Gal-3, or sST2 can identify patients with HFpEF compared to individuals without heart failure but cannot differentiate HFpEF from HFrEF. BNP is higher in and is better at differentiating HFrEF from HFpEF. Indices that incorporate GDF-15, Gal-3, or sST2 as well as BNP show promise in differentiating HFpEF from HFrEF.

Available only for authorised users

Borlaug BA, Paulus WJ (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32:670–679CrossRefPubMed

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259. https://doi.org/10.1056/NEJMoa052256CrossRefPubMed

Chow B, Rabkin SW (2015) The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis. Heart Fail Rev 20:291–303. https://doi.org/10.1007/s10741-015-9471-1CrossRefPubMed

Warbrick I, Rabkin SW (2019) Effect of the peptides relaxin, neuregulin, ghrelin and glucagon-like prptide-1 on cardiomyocyte factors involved in the molecular mechanisms leading to diastolic dysfunction and/or heart failure with preserved ejection fraction. Peptides 111:33–41CrossRefPubMed

Warbrick I, Rabkin SW (2019) Hypoxia-inducible factor 1-alpha (HIF-1α) as a factor mediating the relationship between obesity and heart failure with preserved ejection fraction. Obes Rev 20:291–303CrossRef

Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of. Eur Heart J 37:2129–2200. https://doi.org/10.1093/eurheartj/ehw128CrossRefPubMed

Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer. J Am Coll Cardiol 70:776–803. https://doi.org/10.1016/j.jacc.2017.04.025CrossRefPubMed

Moher D, Liberati A, Tetzlaff J et al (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 6:e1000097CrossRefPubMedPubMedCentral

Higgins J, Thomas J, Chandler J, et al (2019) Cochrane Handbook for systematic reviews of interventions, 6.0. Cochrane

10.

Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 94:11514–11519CrossRefPubMedPubMedCentral

11.

Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L (1997) PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1354:40–44CrossRefPubMed

12.

Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang HP, Breit SN (1999) MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol 65:2–5CrossRefPubMed

13.

Unsicker K, Spittau B, Krieglstein K (2013) The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 24:373–384. https://doi.org/10.1016/j.cytogfr.2013.05.003CrossRefPubMed

14.

Fairlie WD, Zhang HP, Wu WM, Pankhurst SL, Bauskin AR, Russell PK, Brown PK, Breit SN (2001) The propeptide of the transforming growth factor-beta superfamily member, macrophage inhibitory cytokine-1 (MIC-1), is a multifunctional domain that can facilitate protein folding and secretion. J Biol Chem 276:16911–16918CrossRefPubMed

15.

Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC (2006) The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98:351–360CrossRefPubMed

16.

Zhang Y, Moszczynski LA, Liu Q et al (2017) Over-expression of growth differentiation factor 15 (GDF15) preventing cold ischemia reperfusion (I/R) injury in heart transplantation through Foxo3a signaling. Oncotarget 8:36531–36544. https://doi.org/10.18632/oncotarget.16607CrossRefPubMedPubMedCentral

17.

Heger J, Schiegnitz E, von Waldthausen D et al (2010) Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J Cell Physiol 224:120–126. https://doi.org/10.1002/jcp.22102CrossRefPubMed

18.

Wang T, Liu J, McDonald C et al (2017) GDF15 is a heart-derived hormone that regulates body growth. EMBO Mol Med 9:1150–1164. https://doi.org/10.15252/emmm.201707604CrossRefPubMedPubMedCentral

19.

Cotter G, Voors AA, Prescott MF et al (2015) Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail 17:1133–1143. https://doi.org/10.1002/ejhf.331CrossRefPubMed

20.

Bettencourt P, Ferreira-Coimbra J, Rodrigues P et al (2018) Towards a multi-marker prognostic strategy in acute heart failure: a role for GDF-15. ESC Heart Fail 5:1017–1022. https://doi.org/10.1002/ehf2.12301CrossRefPubMedPubMedCentral

21.

Lin J-F, Wu S, Hsu S-Y et al (2014) Growth-differentiation factor-15 and major cardiac events. Am J Med Sci 347:305–311. https://doi.org/10.1097/MAJ.0b013e318291cd4eCrossRefPubMed

22.

Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054–1060CrossRefPubMed

23.

Sharma A, Stevens SR, Lucas J et al (2017) Utility of growth differentiation Factor-15, A marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study. JACC Heart Fail 5:724–734. https://doi.org/10.1016/j.jchf.2017.07.013CrossRefPubMedPubMedCentral

24.

Lok DJ, Klip IT, Lok SI et al (2013) Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol 112:831–837. https://doi.org/10.1016/j.amjcard.2013.05.013CrossRefPubMed

25.

Richter B, Koller L, Hohensinner PJ et al (2013) A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol 168:1251–1257. https://doi.org/10.1016/j.ijcard.2012.11.052CrossRefPubMed

26.

Dinh W, Futh R, Lankisch M et al (2011) Growth-differentiation factor-15: a novel biomarker in patients with diastolic dysfunction? Arq Bras Cardiol 97:65–75CrossRefPubMed

27.

Santhanakrishnan R, Chong JPC, Ng TP et al (2012) Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 14:1338–1347. https://doi.org/10.1093/eurjhf/hfs130CrossRefPubMed

28.

Sinning C, Kempf T, Schwarzl M et al (2017) Biomarkers for characterization of heart failure - distinction of heart failure with preserved and reduced ejection fraction. Int J Cardiol 227:272–277. https://doi.org/10.1016/j.ijcard.2016.11.110CrossRefPubMed

29.

Stahrenberg R, Edelmann F, Mende M et al (2010) The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 12:1309–1316. https://doi.org/10.1093/eurjhf/hfq151CrossRefPubMedPubMedCentral

30.

Baessler A, Strack C, Rousseva E et al (2012) Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur J Heart Fail 14:1240–1248. https://doi.org/10.1093/eurjhf/hfs116CrossRefPubMed

31.

Sanders-van Wijk S, van Empel V, Davarzani N et al (2015) Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail 17:1006–1014. https://doi.org/10.1002/ejhf.414CrossRefPubMed

32.

Tromp J, Khan MAF, Klip IT et al (2017) Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc. https://doi.org/10.1161/JAHA.116.003989

33.

Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K (1994) Galectins: a family of animal beta-galactoside-binding lectins. Cell 76:597–598CrossRefPubMed

34.

Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, Yagi F, Kasai K (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572:232–254CrossRefPubMed

35.

Chen S-C, Kuo P-L (2016) The role of galectin-3 in the kidneys. Int J Mol Sci 17:565. https://doi.org/10.3390/ijms17040565CrossRefPubMedPubMedCentral

36.

Li X, Tang X, Lu J, Yuan S (2018) Therapeutic inhibition of galectin-3 improves cardiomyocyte apoptosis and survival during heart failure. Mol Med Rep 17:4106–4112. https://doi.org/10.3892/mmr.2017.8323CrossRefPubMed

37.

Marin-Royo G, Gallardo I, Martinez-Martinez E et al (2018) Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity. Dis Model Mech. https://doi.org/10.1242/dmm.032086

38.

Nguyen M-N, Su Y, Kiriazis H et al (2018) Upregulated galectin-3 is not a critical disease mediator of cardiomyopathy induced by beta2-adrenoceptor overexpression. Am J Physiol Heart Circ Physiol 314:H1169–H1178. https://doi.org/10.1152/ajpheart.00337.2017CrossRefPubMed

39.

Hashmi S, Al-Salam S (2015) Galectin-3 is expressed in the myocardium very early post-myocardial infarction. Cardiovasc Pathol 24:213–223. https://doi.org/10.1016/j.carpath.2014.12.001CrossRefPubMed

40.

Wu C-K, Su M-Y, Lee J-K et al (2015) Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci Rep 5:17007. https://doi.org/10.1038/srep17007CrossRefPubMedPubMedCentral

41.

Flores-Ramírez R, A-L J, González-González JG, Ordaz-Farías A, González-Carrillo LE, Carrizales-Sepúlveda EF, Vera-Pineda R (2017) Global longitudinal strain as a biomarker in diabetic cardiomyopathy. A comparative study with Gal-3 in patients with preserved ejection fraction. Flores. Arch Cardiol Mex 87:278–285PubMed

42.

Polat V, Bozcali E, Uygun T et al (2016) Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. Acta Cardiol 71:191–197. https://doi.org/10.2143/AC.71.2.3141849CrossRefPubMed

43.

Beltrami M, Ruocco G, Dastidar AG et al (2016) Additional value of galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clin Chim Acta 457:99–105. https://doi.org/10.1016/j.cca.2016.04.007CrossRefPubMed

44.

Kotby AA, Youssef OI, Elmaraghy MO, El Sharkawy OS (2017) Galectin-3 in children with chronic heart failure with normal and reduced ejection fraction: relationship to disease severity. Pediatr Cardiol 38:95–102. https://doi.org/10.1007/s00246-016-1488-2CrossRefPubMed

45.

Edelmann F, Holzendorf V, Wachter R et al (2015) Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 17:214–223. https://doi.org/10.1002/ejhf.203CrossRefPubMed

46.

Shah RV, Chen-Tournoux AA, Picard MH et al (2010) Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 12:826–832. https://doi.org/10.1093/eurjhf/hfq091CrossRefPubMedPubMedCentral

47.

Boraschi D, Tagliabue A (2013) The interleukin-1 receptor family. Semin Immunol 25:394–407. Doi. https://doi.org/10.1016/j.smim.2013.10.023

48.

Pascual-Figal DA, Januzzi JL (2015) The biology of ST2: the international ST2 consensus panel. Am J Cardiol 115:3B–7B. https://doi.org/10.1016/j.amjcard.2015.01.034CrossRefPubMed

49.

Iwahana H, Yanagisawa K, Ito-Kosaka A et al (1999) Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 264:397–406CrossRefPubMed

50.

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan T, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490CrossRefPubMed

51.

Weinberg EO, Shimpo M, De Keulenaer GW et al (2002) Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106:2961–2966CrossRefPubMedPubMedCentral

52.

Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie A, Lee RT (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117:1538–1549CrossRefPubMedPubMedCentral

53.

Kakkar R, Lee RT (2008) The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7:827–840. https://doi.org/10.1038/nrd2660CrossRefPubMedPubMedCentral

54.

Seki K, Sanada S, Kudinova AY et al (2009) Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2:684–691. https://doi.org/10.1161/CIRCHEARTFAILURE.109.873240CrossRefPubMed

55.

Pascual-Figal DA, Perez-Martinez MT, Asensio-Lopez MC et al (2018) Pulmonary production of soluble ST2 in heart failure. Circ Heart Fail 11:e005488. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005488CrossRefPubMed

56.

Bayes-Genis A, Gonzalez A, Lupon J (2018) ST2 in heart failure. Circ Heart Fail 11:e005582. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005582CrossRefPubMed

57.

Wang Y-C, Yu C-C, Chiu F-C et al (2013) Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail 19:163–168. https://doi.org/10.1016/j.cardfail.2013.01.010CrossRefPubMed

58.

Zile MR, Baicu CF, Ikonomidis JS et al (2015) Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131:1247–1259. https://doi.org/10.1161/CIRCULATIONAHA.114.013215CrossRefPubMedPubMedCentral

59.

Ruocco G, Evangelista I, Franci B et al (2019) Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome. J Cardiovasc Med (Hagerstown) 20:81–90. https://doi.org/10.2459/JCM.0000000000000741CrossRef

60.

Meijers WC, van der Velde AR, Muller Kobold AC et al (2017) Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail 19:357–365. https://doi.org/10.1002/ejhf.669CrossRefPubMed

61.

AbouEzzeddine OF, Haines P, Stevens S et al (2015) Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure). JACC heart fail 3:245–252. https://doi.org/10.1016/j.jchf.2014.10.009CrossRefPubMedPubMedCentral

62.

Vaidya GN, Abramov D (2018) Echocardiographic evaluation of diastolic function is of limited value in the diagnosis and management of HFpEF. J Card Fail 24:392–396. https://doi.org/10.1016/j.cardfail.2018.02.008CrossRefPubMed

Title: The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review
Authors: Simon W. Rabkin
Jacky K. K. Tang
Publication date: 01-07-2021
Publisher: Springer US
Keywords: Heart Failure
Biomarkers
Published in: Heart Failure Reviews / Issue 4/2021
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-020-09913-3

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

High-density lipoprotein-mediated cardioprotection in heart failure

The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19

Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets

A meta-analysis of microRNA expression profiling studies in heart failure

Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis

The role of mechanotransduction in heart failure pathobiology—a concise review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page